Skip to content
BidBenchmark

Contract award

MAPP BIOPHARMACEUTICAL, INC.

THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION.
PIID
75A50122C00076
Award key
CONT_AWD_75A50122C00076_7505_-NONE-_-NONE-
Recipient UEI
M9V9QTHR1H28
Source as of
—
Current award value
$155,212,6883
Obligated to date
$155,212,6882
Potential with options
$299,926,7343
Awarding agency
Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response
Place of performance
San Diego, California
Set-aside
No set-aside used
Pricing
Cost Plus Fixed Fee
Competition
Full and Open Competition1 offers received
Period of performance
Sep 28, 2022 — Dec 31, 2032Through Jul 31, 2036 if all options are exercised
Benchmark category
Unclassified

Transaction history

Every action recorded against this award, in the order the government reported them.

ModAction dateReasonObligationValue at action
0Sep 28, 2022Initial award$78,480,810.00$155,212,688.03
P00001Feb 10, 2023M$0.00$155,212,688.03
P00002Apr 19, 2023B$19,833,117.26$155,212,688.03
P00003Aug 7, 2023B$12,563,457.77$155,212,688.03
P00004Mar 8, 2024B$0.00$155,212,688.03
P00005May 21, 2024B$0.00$155,212,688.03
P00006Sep 24, 2024B$0.00$155,212,688.03
P00007Nov 15, 2024B$0.00$155,212,688.03
P00008Dec 13, 2024B$0.00$155,212,688.03
P00009Jan 30, 2025M$0.00$155,212,688.03
P00010Feb 28, 2025M$0.00$155,212,688.03
P00011Mar 28, 2025B$0.00$155,212,688.03
P00012May 7, 2025M$0.00$155,212,688.03
P00013Jul 7, 2025M$0.00$155,212,688.03
P00014Aug 25, 2025M$0.00$155,212,688.03
P00015Feb 20, 2026B$0.00$155,212,688.03
P00016May 14, 2026B$0.00$155,212,688.03
P00017Jul 13, 2026B$0.00$155,212,688.03
P00018Sep 14, 2026B$44,335,303.00$155,212,688.03

Provenance

Which source record produced each displayed rollup figure.

FieldSourceFileRetrievedParserArtifact hash
awarding_agency_idUSAspending.gov—Sep 16, 2026usaspending_contract_csv@2026.08.2fed29c00e11f
contractor_idUSAspending.gov—Sep 16, 2026usaspending_contract_csv@2026.08.2fed29c00e11f
current_award_valueUSAspending.gov—Sep 16, 2026usaspending_contract_csv@2026.08.2fed29c00e11f
naics_codeUSAspending.gov—Sep 16, 2026usaspending_contract_csv@2026.08.2fed29c00e11f
potential_award_valueUSAspending.gov—Sep 16, 2026usaspending_contract_csv@2026.08.2fed29c00e11f
psc_codeUSAspending.gov—Sep 16, 2026usaspending_contract_csv@2026.08.2fed29c00e11f
total_obligatedUSAspending.gov—Sep 16, 2026usaspending_contract_csv@2026.08.2fed29c00e11f

Sources and method

Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.

This page is a record of one federal award, assembled from the transactions the government published against it. Note 1 describes where the rollup came from. Values are award values, not unit prices.

  1. 1Rollup values derive from 19 transaction records parsed from USAspending.gov, retrieved Sep 16, 2026 by transform awards@2026.08.1.
  2. 2Obligations are the sum of signed federal action obligations across all transactions; deobligations are negative and remain negative.
  3. 3Current and potential award values are taken from the latest reported action, not summed across modifications.
75A50122C00076 — MAPP BIOPHARMACEUTICAL, INC. · BidBenchmark